Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited to Participate in the Jefferies 2019 Healthcare Conference
JERSEY, Channel Islands , May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop , will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:30
View HTML
Toggle Summary Quotient Ltd. Announces FDA Approval of Seven Additional Blood Bank Reagents
JERSEY, Channel Islands , May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), an established, commercial-stage diagnostics company (the Company), today announced the U.S. Food and Drug Administration ( FDA ) has approved the commercialization of seven additional blood bank reagents
View HTML
Toggle Summary Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands , May 14, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2019 will be released before market open on Tuesday, May 28, 2019 .
View HTML
Toggle Summary Quotient Limited Receives European CE Mark for its Initial IH Microarray
JERSEY, Channel Islands , May 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced receipt of the CE Mark (Conformité Européenne) for its initial Immunohematology (IH) Microarray for
View HTML
Toggle Summary Quotient Limited Announces Initial SDS EU Field Trial Performance Data for MosaiQ™
JERSEY, Channel Islands , April 24, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive EU field trial performance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray.
View HTML
Toggle Summary Quotient Limited to Participate in the Cowen and Company 39th Annual Health Care Conference
JERSEY, Channel Islands , March 07, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop , will present at the Cowen and Company 39 th Annual Health Care Conference on Monday, March
View HTML
Toggle Summary Quotient Limited to Host Investor Day and Ring Closing Bell at the NASDAQ on March 4, 2019
JERSEY, Channel Islands , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company will host an Investor Day on Monday, March 4, 2019 from 1:00pm – 3:00pm ET , in New York, NY .
View HTML
Toggle Summary Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
JERSEY, Channel Islands , Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt , will present at the 8 th Annual SVB Leerink Global Healthcare Conference
View HTML
Toggle Summary Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fiscal 2019 Results
Development data provides positive results for extended IH microarray panel Field trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of 15% in the quarter and 12% year to date JERSEY, Channel Islands , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited
View HTML
Toggle Summary Quotient Limited to Report Fiscal Third Quarter 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2018 , will be released before market open on Thursday, January 31, 2019 .
View HTML